Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shandong University
• Treatments: Amoxicillin; Esomeprazole; Tinidazole

Criteria

Inclusion Criteria:

• Patients who were intend to undergo upper endoscopy for any purpose and volunteered to written inform consent.

Exclusion Criteria:

• negative in rapid urease test (RUT)

• previous standard eradication therapy for H. pylori;

• history of esophagectomy or gastrectomy;

• gastrointestinal malignancy;

• contraindications or allergic to study drugs;

• user of taking medicine that may affect the result of the study within 4 weeks (e.g., proton-pump inhibitors, H2-receptor antagonists, bismuth or antibiotics etc.);

• cardiopulmonary, hepatic or renal insufficiency, and/or severe current diseases or malignancy;

• pregnant or lactating women;

• participants of other trial within the past 3 months;

• unwilling or unable to participate in the study.